An adaptive phase I design for identifying a biologically optimal dose for dual agent drug combinations

Sumithra J Mandrekar, Yue Cui, Daniel J. Sargent

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Historically, designs for dose seeking trials using chemotherapeutic drug combinations have been geared towards finding the maximum tolerated dose, with safety as the primary outcome. With target based agents whose dose-efficacy curves are unknown and dose-toxicity relationships may be minimal, alternative designs are needed. In this paper, we propose an extension to an adaptive single agent dose-finding design previously reported. A generalization of the continuation ratio model allowing separate toxicity and efficacy curves for each agent in a dual agent combination, generating a dose success surface for the combination, is proposed. A continual reassessment approach with a straightforward dose selection criterion using the accumulated data from all patients treated to that point is employed. Our simulation studies demonstrate favourable operating characteristics in terms of experimentation and recommendation rates, and the average sample size, under a variety of scenarios. The proposed approach allowing the incorporation of both the toxicity and efficacy of each agent into the identification of an optimal dosing region for combination is novel and warrants further consideration.

Original languageEnglish (US)
Pages (from-to)2317-2330
Number of pages14
JournalStatistics in Medicine
Volume26
Issue number11
DOIs
StatePublished - May 20 2007

Fingerprint

Maximum Tolerated Dose
Drug Combinations
Sample Size
Patient Selection
Dose
Drugs
Safety
Toxicity
Efficacy
Dose Finding
Curve
Operating Characteristics
Experimentation
Continuation
Recommendations
Design
Simulation Study
Unknown
Scenarios
Target

Keywords

  • Combination therapy
  • Continual reassessment method
  • Continuation ratio model
  • Efficacy
  • Phase I
  • Toxicity

ASJC Scopus subject areas

  • Epidemiology

Cite this

An adaptive phase I design for identifying a biologically optimal dose for dual agent drug combinations. / Mandrekar, Sumithra J; Cui, Yue; Sargent, Daniel J.

In: Statistics in Medicine, Vol. 26, No. 11, 20.05.2007, p. 2317-2330.

Research output: Contribution to journalArticle

@article{35aa0984e45f49aabbc5763ef2b82b6d,
title = "An adaptive phase I design for identifying a biologically optimal dose for dual agent drug combinations",
abstract = "Historically, designs for dose seeking trials using chemotherapeutic drug combinations have been geared towards finding the maximum tolerated dose, with safety as the primary outcome. With target based agents whose dose-efficacy curves are unknown and dose-toxicity relationships may be minimal, alternative designs are needed. In this paper, we propose an extension to an adaptive single agent dose-finding design previously reported. A generalization of the continuation ratio model allowing separate toxicity and efficacy curves for each agent in a dual agent combination, generating a dose success surface for the combination, is proposed. A continual reassessment approach with a straightforward dose selection criterion using the accumulated data from all patients treated to that point is employed. Our simulation studies demonstrate favourable operating characteristics in terms of experimentation and recommendation rates, and the average sample size, under a variety of scenarios. The proposed approach allowing the incorporation of both the toxicity and efficacy of each agent into the identification of an optimal dosing region for combination is novel and warrants further consideration.",
keywords = "Combination therapy, Continual reassessment method, Continuation ratio model, Efficacy, Phase I, Toxicity",
author = "Mandrekar, {Sumithra J} and Yue Cui and Sargent, {Daniel J.}",
year = "2007",
month = "5",
day = "20",
doi = "10.1002/sim.2707",
language = "English (US)",
volume = "26",
pages = "2317--2330",
journal = "Statistics in Medicine",
issn = "0277-6715",
publisher = "John Wiley and Sons Ltd",
number = "11",

}

TY - JOUR

T1 - An adaptive phase I design for identifying a biologically optimal dose for dual agent drug combinations

AU - Mandrekar, Sumithra J

AU - Cui, Yue

AU - Sargent, Daniel J.

PY - 2007/5/20

Y1 - 2007/5/20

N2 - Historically, designs for dose seeking trials using chemotherapeutic drug combinations have been geared towards finding the maximum tolerated dose, with safety as the primary outcome. With target based agents whose dose-efficacy curves are unknown and dose-toxicity relationships may be minimal, alternative designs are needed. In this paper, we propose an extension to an adaptive single agent dose-finding design previously reported. A generalization of the continuation ratio model allowing separate toxicity and efficacy curves for each agent in a dual agent combination, generating a dose success surface for the combination, is proposed. A continual reassessment approach with a straightforward dose selection criterion using the accumulated data from all patients treated to that point is employed. Our simulation studies demonstrate favourable operating characteristics in terms of experimentation and recommendation rates, and the average sample size, under a variety of scenarios. The proposed approach allowing the incorporation of both the toxicity and efficacy of each agent into the identification of an optimal dosing region for combination is novel and warrants further consideration.

AB - Historically, designs for dose seeking trials using chemotherapeutic drug combinations have been geared towards finding the maximum tolerated dose, with safety as the primary outcome. With target based agents whose dose-efficacy curves are unknown and dose-toxicity relationships may be minimal, alternative designs are needed. In this paper, we propose an extension to an adaptive single agent dose-finding design previously reported. A generalization of the continuation ratio model allowing separate toxicity and efficacy curves for each agent in a dual agent combination, generating a dose success surface for the combination, is proposed. A continual reassessment approach with a straightforward dose selection criterion using the accumulated data from all patients treated to that point is employed. Our simulation studies demonstrate favourable operating characteristics in terms of experimentation and recommendation rates, and the average sample size, under a variety of scenarios. The proposed approach allowing the incorporation of both the toxicity and efficacy of each agent into the identification of an optimal dosing region for combination is novel and warrants further consideration.

KW - Combination therapy

KW - Continual reassessment method

KW - Continuation ratio model

KW - Efficacy

KW - Phase I

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=34248324496&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248324496&partnerID=8YFLogxK

U2 - 10.1002/sim.2707

DO - 10.1002/sim.2707

M3 - Article

C2 - 17016867

AN - SCOPUS:34248324496

VL - 26

SP - 2317

EP - 2330

JO - Statistics in Medicine

JF - Statistics in Medicine

SN - 0277-6715

IS - 11

ER -